What We Do
From Zika to Dengue, mosquito-born illnesses are growing in developing and developed countries. FlaviTech detects diseases earlier by developing and commercializing the use of antibodies against non-structural viral proteins, eliminating cross-reactivity between viruses.
The Product
- [PROTOTYPE] Non-structural protein assay with diagnostic algorithm
- [IDEATION] At home test kits (lateral flow devices), in-field test kits
(mobile detection), point-of-care testing kits and instrumentation, and
testing services and interpretative analysis - [PROVISIONAL PATENT] Reporter virus neutralization assay
Target Customer Pain Points
- Globally women in their child bearing years fear the possibility of birthing a microcephalic child
- Hospitals, clinics, primary care and OB/GYN offices need solutions for faster diagnosis of infection and disease
- Research and academic institutions need better solutions for human and animal testing to aid in developing vaccines and treatments
Differentiation
- Assay turnaround time less than 48 hrs (CDC turnaround measured in wks) • No cross-reactivity across viruses
- Laser-focus on each end-user’s experience not only innovating the science
Market Size
The market for infectious disease testing is expected to grow from $16.8 billion in 2015 to $20.9 billion in 2020.
Progress & Milestones
- Developed prototype zika virus detection system called the multiplex microsphere immunoassay (MIA); conditionally approved for patient sample tests in New York State
- Proof-of-concept of reporter virus neutralization assay; ready for clinical use; provisional patent filed; publication pending
- Partnership with Galveston National Laboratory and Brazilian government
- Validation testing planned in Brazil and neighboring countries
Management Team
- Pei-Yong Shi, PhD
- Alexander Vo, PhD
- Ryan Westberry, MS, MBA
Download this document